Background: Evaluation of lymphedema and lymph node metastasis in humans has relied primarily on invasive or radioactive modalities. While noninvasive technologies such as magnetic resonance imaging (MRI) offer the potential for true three-dimensional imaging of lymphatic structures, invasive modalities, such as optical fluorescence microscopy, provide higher resolution and clearer delineation of both lymph nodes and lymphatic vessels. Thus, contrast agents that image lymphatic vessels and lymph nodes by both fluorescence and MRI may further enhance our understanding of the structure and function of the lymphatic system. Recent applications of bimodal (fluorescence and MR) contrast agents in mice have not achieved clear visualization of lymphatic vessels and nodes. Here the authors describe the development of a nanoparticulate contrast agent that is taken up by lymphatic vessels to draining lymph nodes and detected by both modalities.
INTRODUCTION V
ISUALIZATION OF THE LYMPHATIC SYSTEM plays a significant role in assessing patients with various malignancies and lymphedema. 1, 2 Current patient imaging modalities, such as lymphography and lymphoscintigraphy, are invasive and may expose patients and physicians to radiation. 3, 4 In particular, lymphography, in addition to being technically difficult, causes significant patient discomfort and may lead to potential complications such as reaction to the dye, pulmonary emboli, and wound infections. 3, 5 In animal models, lymphography has been predominantly limited to the use of Evans blue dye 7 and fluorescently labeled dextrans. 8 Lymphoscintigraphy, which is traditionally used to localize sentinel lymph nodes, has low temporal and spatial resolution and fails to adequately demonstrate the direct connection of lymphatic vessels to the associated nodes. Moreover, vascular spillage of the radiotracer may lead to the labeling of nonsentinel lymph nodes. 4, 6 As a result of these limitations and combined with the promise of magnetic resonance imaging (MRI) for the noninvasive visualization of both lymphatic vessel structure and lymph nodes, various contrast agents that enhance the MR signal in vivo have been introduced. [9] [10] [11] [12] [13] The design of these agents needs to take into account current understanding of interstitial transport mechanics and function of lymphatic vessels. 1, 14 Thus, to facilitate noninvasive visualization of both lymphatic vessels and lymph nodes, 11, 13 an ideal contrast agent needs to be sufficiently large to prevent leakage into blood vessels. At the same time, the agent needs to be sufficiently small for rapid transport through the lymphatics during the time course of the imaging experiment.
Despite significant advances in nanoparticulate-based systems, clear visualization of both lymphatic vessels and lymph nodes by both MRI and fluorescence in living animals has been limited. 13 Here we describe the development and demonstration of a bimodal nanoparticulate contrast agent which has been optimized for fluorescent microscopy and MRI. Upon subcutaneous administration, the nanoparticles are quickly (within minutes) taken up by the lymphatic vessels to the draining nodes and are detected by MRI. Computational processing of our images with in-house developed software (Yale Bioimage Suite medical image analysis software) allowed further refinement and realization of high resolution images. This bimodal agent thus offers a noninvasive, sensitive, nonisotopic, and dynamic means of evaluating the lymphatic vasculature and nodes, potentially enabling further evaluation of animal models of lymphatic system pathology and extrapolation to clinical settings.
MATERIALS AND METHODS
All experiments were conducted on female C57BL/6J mice (8-12 weeks old) obtained from the Jackson Laboratory (Bar Harbor, Maine) and in accordance with established animal protocols maintained and approved by the Institutional Animal Care and Use Committee at Yale University and Yale School of Medicine.
Synthesis and characterization of the nanoparticulate contrast agent
We selected polyamidoamine dendrimers (PAMAM) (generation 6 (G6) diameter ϭ 7.2 nm, 256 theoretical functional groups) as the foundation for the design of the bimodal imaging construct because of their demonstrated potential as nanoscopic polymers for conjugation to a variety of agents. 15, 16 The design criteria necessitated that the final size of these particles, following attachment of imaging agents, be large enough to prevent their leakage into blood capillaries. Additionally, the particles could not be larger than 30-50 nm as that would reduce their trafficking from the injection site (on the order of days), thus slowing lymphatic drainage and negatively impacting the utility of the imaging procedure. 3 These two requirements; the size of the agent for exclusive and rapid uptake by the lymphatic system combined with the need to attain high paramagnetic relaxivity for MR, dictated our design of the bimodal nanoparticle.
The PAMAM core was conjugated with SCN-DTPA, NHS-PEG5000-FITC and NHS-PEG3400-OH in a molar ratio of (40:3:7) using a single reaction step (Fig. 1A) . Polyethylene glycol (PEG) was then tethered to the dendrimer core for several reasons: first, PEG is a linear polymer that imparts flexibility and colloidal stability to the attached PAMAM core while also drawing water into the construct volume. This feature is useful for maximizing T1 contrast that depends on water relaxation. Second, by stabilizing the surface with PEG, useful properties such as enhanced solubility, biocompatibility, lower immunogenicity, reduced toxicity, and desirable pharmacokinetics can be introduced into the construct. 17 These critical properties allow for safe and efficient use of this technology in vivo.
Following dialysis of the construct, a 100-fold molar excess of GdCl 3 .6H20 was added and allowed to equilibrate for 48 h at room temperature with the construct; this was followed by a second round of dialysis to remove unchelated gadolinium III. The final product contained up to 23 moles of gadolinium per mole of dendrimer assessed by a colorimetric Arsenazo III assay (Fig. 1B) and showed an enhanced T1 relaxation compared to free Gd/DTPA at the same concentration (Fig. 1C) . FT-IR and NMR spectra of the conjugate confirmed the formation of amide conjugates, and fluorescence spectroscopy (excitation 488 nm and emission at 520 nm) confirmed the presence of fluorescein. Final conjugate size was assessed by dynamic light scattering and showed that constructs were distributed in size with a mean diameter of 30 Ϯ 10 nm.
The size of the constructs was measured by dynamic light scattering (DLS). The instrument 
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consisted of a diode pumped laser (Verdi V-2/V-5, Coherent) operating at 532 nm, an ALV-SP S/N 30 goniometer (ALV-GmbH, Langen, Germany) with index matching vat filled with doubly filtered (0.1 mm) toluene, and an ALV-500 correlator. Low concentrations of constructs (Ͻ5 ug/mL) were pipetted into a cleaned borosilicate culture tube before measuring the intensity of the auto-correlation function at a 90°scattering angle. The hydrodynamic radius, RH, was determined by nonlinear least squares fitting (ALV software) of the resulting second order cumulants.
Magnetic resonance imaging
MRI of the mice was performed using a 4.7T Bruker scanner operating at 4T. The mice that underwent MR imaging were anesthetized with 250 L i.p. injections of ketamine (10 mg/mL) and xylazine (1 mg/mL) and examined for pain response to toe pinch to ensure adequate anesthesia prior to contrast injections. The tip of a 30 G needle was broken off the plastic base and fitted into a polyethylene tube with 28 mm I.D. (BD Biosciences, Sparks, MD). The tubing was also fitted into another 30 G needle attached to a 1 mL syringe containing contrast at 15 mg/mL in PBS. The anesthetized mouse was secured onto a plexiglass custom-constructed coil holder with the imaging area of interest centered in the coil. The needle was inserted subcutaneously into the hind footpad and secured using tape. The animals were imaged prior to contrast injection to generate a control image. Fifty L of contrast was then injected while the animal remained secured within the magnet. This procedure was repeated with the needle fixed subcutaneously in the tail of anesthetized mice 3 cm proximal to the tip.
Injection was followed by dynamic acquisitions using a 4T Bruker AVANCE system equipped with 5.4 KHz/cm, 150 ms rise time gradients. A series of imaging sessions were then performed to detect the contrast within the lymphatic vessels and lymph nodes. This remote injection technique facilitated registration and subsequent processing of images obtained both before and after injections. All images were obtained using a T1-weighted 3D fast gradient echo (GEFI) pulse sequence.
MRI image processing
Contrast uptake was quantified by subtraction of the reference image (before injection) from the target image (after agent injection). Prior to the subtraction, the images were registered to account for any movement between scans and intensity normalized to correct for the different dynamic ranges in the images. The intensity normalization was based on a kmeans segmentation of the image to identify the histogram peak corresponding to soft tissue (muscle) which is assumed to be unchanged between the two images and by scaling the reference image to have the same soft-tissue mean as the reference image. 18 All image analysis was performed using the Yale BioImage Suite medical image analysis software package. All difference MR images were overlayed on the anatomical control images.
Optical microscopy: fluorescence and Evans Blue dye imaging
The bimodal nanoparticulate contrast agent was diluted to a concentration of 15 mg/mL in PBS. Fifty L of the dendrimer was injected subcutaneously into each of the hind footpads of the animals using a 1 mL syringe and a 30 G needle. Mice were sacrificed using a CO 2 chamber 30 min following injection. The popliteal lymph node was exposed by means of a vertical skin incision over the calf and retraction of the skin. The inguinal lymph nodes were exposed by means of a vertical midline skin incision over the abdomen and thorax and retraction of the skin. The para-aortic lymph nodes were exposed by a midline incision of the abdomen and retraction of the intestines and mesentery revealing the bifurcation of the aorta. These nodes and associated lymphatic vessels were all visualized using a Zeiss Lumar ® fluorescent dissecting microscope. Absence of detectable fluorescence in the tissues and vasculature of these animals confirmed full uptake of contrast agent in the lymphatic vessels and lymph nodes.
To visualize the lymphatic vessels in the tail, the mice were anesthetized as above, and 10 L of contrast at a concentration of 15 mg/mL was injected subcutaneously in the tail 3 cm proximal to the tip. Images were acquired as dis-cussed above, 10 min following injection. Evans blue dye was injected in a similar manner and lymph nodes were exposed as described above and imaged using a Zeiss Stemi ® 2000-C dissecting microscope.
RESULTS

MRI detection of lymphatic vessels and lymph nodes
Our initial studies focused on demonstrating the utility of the nanoparticulate contrast agent in highlighting lymphatic vessels draining to lymph nodes in the hind limb of living mice. We observed that 15 min after subcutaneous injection into the hind footpad, the agent readily entered lymphatic vessels of the hind limb that drain towards the popliteal lymph node (Fig.  2A) . Two distinct afferent lymphatic vessels coursing towards the popliteal lymph node could be seen in subtracted MR images of the hind limb following contrast administration and are clearly distinct after subtraction of the pre-injection image (Fig. 2B and supplementary movie online). We also observed contrast enhancement in efferent vessels at later times following injection (Fig. 2A) . Strikingly, accumulation of the contrast agent in the popliteal node and contrast in efferent vessels was observed for over 45 min postinjection in sharp 
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contrast to the disappearance of an equivalent dose of free gadolinium/DTPA (Fig. 3) .
Verification of MR images by fluorescence and Evans Blue dye lymphography
MR images obtained with the bimodal agent were then compared to high resolution fluorescence microscopy of lymphatic uptake. Fluorescence microscopy experiments were performed using the same procedures as the MRI experiments. Mice were euthanized 30 min following injection of the contrast agent and the popliteal, inguinal, and para-aortic lymph nodes were exposed and visualized using high resolution stereo-fluorescence microscopy (Figs. 4A-4C ). Fluorescence imaging of the above mentioned lymph nodes showed high concordance with the lymphatic vessels and nodes visible in the subtracted MR images (Fig.  4G ) yielding nearly identical images by both modalities. Additionally, the two afferent lymphatic vessels seen by MRI draining into the popliteal lymph node (Fig. 2B) were also seen by fluorescence microscopy (Fig. 4A) . Lymph nodes and associated lymphatic vessels were more clearly visible by fluorescence microscopy compared to standard lymphography using Evans blue dye (Figs. 4D-4F ). Additionally, the nanoparticulate agent, in sharp contrast to the Evans blue dye, showed a more defined distribution within the node. A more prominent signal was detected in the lymph node medulla and subcapsular sinus, most evident in the inguinal and para-aortic lymph nodes (Figs. 4B and 4C ). This may be attributed to the fact that Evans blue dye is conjugated to plasma proteins, 19 and that lymph nodes are capable of modifying lymph flow and protein concentrations by means of their specialized blood and lymphatic vasculature. 20 Thus, plasma proteins may extravasate from within the lymph node vasculature, causing dye to accumulate within the entire node. The nanoparticlulate contrast however, appears to be more restricted to the medullary and marginal sinuses within the lymph node medulla and subcapsular region.
Examination of tail lymphatics using bimodal nanoparticulate contrast
The efficacy of the bimodal reagent in elucidating the well-studied, unique hexagonal network of lymphatic vessels in the mouse tail 21 was then evaluated. Anesthetized mice were and 5B) and MRI (Fig. 5C ). Both modalities produced similar images revealing the honeycombed lymphatic vessel network in the tail. Moreover, MR revealed the preferential surface localization of these lymphatic structures highlighting the utility of the agent in discerning detailed threedimensional lymphatic distribution.
CONCLUSION
Technology for noninvasive imaging of lymphatic vessels and lymph nodes has been limited by the signal-to-noise ratio and resolution that can be achieved. Several modalities have been proposed to address this issue focusing on the unique ability of nanoparticulates to couple to a high density of paramagnetic chelates, hence enhancing relaxivity. However, these limitations have not been completely overcome due to a variety of factors including optimal contrast agent design, acquisition methods, and postacquisition image processing. In this report, we have incorporated all of these factors and demonstrated the utility of a new nanoscopic agent for high resolution imaging of the lymphatic system. The unique combination of highly sensitive fluorescence lymphography and superior spatial resolution achieved by noninvasive MR yields an approach that promises wide utility in basic science, with potential clinical applications for lymphatic visualization and serial assessment of patients with lymphedema or metastatic disease.
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